Patent ID: 11919966
Assignee: ABLYNX N.V.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 4:
5. The method according to claim 1, wherein said at least one immunoglobulin single variable domain essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:
CDR1 is SEQ ID NO: 73, CDR2 is SEQ ID NO: 90; and CDR3 is SEQ ID NO: 123;
CDR1 is SEQ ID NO: 73, CDR2 is SEQ ID NO: 90; and CDR3 is SEQ ID NO: 118;
CDR1 is SEQ ID NO: 74, CDR2 is SEQ ID NO: 91; and CDR3 is SEQ ID NO: 118;
CDR1 is SEQ ID NO: 74, CDR2 is SEQ ID NO: 92; and CDR3 is SEQ ID NO: 118;
CDR1 is SEQ ID NO: 74, CDR2 is SEQ ID NO: 93; and CDR3 is SEQ ID NO: 118;
CDR1 is SEQ ID NO: 74, CDR2 is SEQ ID NO: 94; and CDR3 is SEQ ID NO: 118;
CDR1 is SEQ ID NO: 74, CDR2 is SEQ ID NO: 95; and CDR3 is SEQ ID NO: 118;
CDR1 is SEQ ID NO: 75, CDR2 is SEQ ID NO: 93; and CDR3 is SEQ ID NO: 118;
CDR1 is SEQ ID NO: 74, CDR2 is SEQ ID NO: 96; and CDR3 is SEQ ID NO: 118;
CDR1 is SEQ ID NO: 74, CDR2 is SEQ ID NO: 97; and CDR3 is SEQ ID NO: 118;
CDR1 is SEQ ID NO: 74, CDR2 is SEQ ID NO: 98; and CDR3 is SEQ ID NO: 119;
CDR1 is SEQ ID NO: 73, CDR2 is SEQ ID NO: 90; and CDR3 is SEQ ID NO: 282;
CDR1 is SEQ ID NO: 73, CDR2 is SEQ ID NO: 90; and CDR3 is SEQ ID NO: 283;
CDR1 is SEQ ID NO: 73, CDR2 is SEQ ID NO: 90; and CDR3 is SEQ ID NO: 284;
CDR1 is SEQ ID NO: 76, CDR2 is SEQ ID NO: 99; and CDR3 is SEQ ID NO: 120;
CDR1 is SEQ ID NO: 77, CDR2 is SEQ ID NO: 100; and CDR3 is SEQ ID NO: 121;
CDR1 is SEQ ID NO: 78, CDR2 is SEQ ID NO: 101; and CDR3 is SEQ ID NO: 122;
CDR1 is SEQ ID NO: 76, CDR2 is SEQ ID NO: 102; and CDR3 is SEQ ID NO: 118;
CDR1 is SEQ ID NO: 77, CDR2 is SEQ ID NO: 103; and CDR3 is SEQ ID NO: 118;
CDR1 is SEQ ID NO: 76, CDR2 is SEQ ID NO: 99; and CDR3 is SEQ ID NO: 118;
CDR1 is SEQ ID NO: 78, CDR2 is SEQ ID NO: 99; and CDR3 is SEQ ID NO: 123;
CDR1 is SEQ ID NO: 79, CDR2 is SEQ ID NO: 104; and CDR3 is SEQ ID NO: 124;
CDR1 is SEQ ID NO: 76, CDR2 is SEQ ID NO: 105; and CDR3 is SEQ ID NO: 124;
CDR1 is SEQ ID NO: 76, CDR2 is SEQ ID NO: 106; and CDR3 is SEQ ID NO: 124;
CDR1 is SEQ ID NO: 80, CDR2 is SEQ ID NO: 106; and CDR3 is SEQ ID NO: 124;
CDR1 is SEQ ID NO: 81, CDR2 is SEQ ID NO: 104; and CDR3 is SEQ ID NO: 124;
CDR1 is SEQ ID NO: 82, CDR2 is SEQ ID NO: 104; and CDR3 is SEQ ID NO: 124;
CDR1 is SEQ ID NO: 83, CDR2 is SEQ ID NO: 104; and CDR3 is SEQ ID NO: 124;
CDR1 is SEQ ID NO: 84, CDR2 is SEQ ID NO: 104; and CDR3 is SEQ ID NO: 124;
CDR1 is SEQ ID NO: 83, CDR2 is SEQ ID NO: 106; and CDR3 is SEQ ID NO: 124;
CDR1 is SEQ ID NO: 83, CDR2 is SEQ ID NO: 107; and CDR3 is SEQ ID NO: 124;
CDR1 is SEQ ID NO: 83, CDR2 is SEQ ID NO: 108; and CDR3 is SEQ ID NO: 124;
CDR1 is SEQ ID NO: 83, CDR2 is SEQ ID NO: 104; and CDR3 is SEQ ID NO: 125;
CDR1 is SEQ ID NO: 85, CDR2 is SEQ ID NO: 109; and CDR3 is SEQ ID NO: 126;
CDR1 is SEQ ID NO: 86, CDR2 is SEQ ID NO: 110; and CDR3 is SEQ ID NO: 126;
CDR1 is SEQ ID NO: 85, CDR2 is SEQ ID NO: 110; and CDR3 is SEQ ID NO: 126;
CDR1 is SEQ ID NO: 87, CDR2 is SEQ ID NO: 111; and CDR3 is SEQ ID NO: 127;
CDR1 is SEQ ID NO: 77, CDR2 is SEQ ID NO: 112; and CDR3 is SEQ ID NO: 128;
CDR1 is SEQ ID NO: 77, CDR2 is SEQ ID NO: 112; and CDR3 is SEQ ID NO: 129;
CDR1 is SEQ ID NO: 77, CDR2 is SEQ ID NO: 113; and CDR3 is SEQ ID NO: 130;
CDR1 is SEQ ID NO: 77, CDR2 is SEQ ID NO: 112; and CDR3 is SEQ ID NO: 130;
CDR1 is SEQ ID NO: 88, CDR2 is SEQ ID NO: 114; and CDR3 is SEQ ID NO: 131;
CDR1 is SEQ ID NO: 88, CDR2 is SEQ ID NO: 115; and CDR3 is SEQ ID NO: 131; or
CDR1 is SEQ ID NO: 88, CDR2 is SEQ ID NO: 116; and CDR3 is SEQ ID NO: 132.